← Back
Data updated: Jun 28, 2026
LXO IRELAND
Specialty Pharmaceuticals
LXO IRELAND is a specialty pharmaceutical company with 2 FDA-approved products.
2007
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
LXO IRELAND's Key Drugs
LXO IRELAND's core commercial portfolio centers on GOPRELTO — its most strategically important drugs approved in the last 15 years.
LXO IRELAND's Recent FDA Approvals
New NDA/BLA approvals for LXO IRELAND over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
LXO IRELAND's Therapeutic Areas
Disease areas where LXO IRELAND has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
LXO IRELAND Pipeline Snapshot
Active clinical trials for LXO IRELAND across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GOPRELTO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2007-03-05
- Latest
- 2023-07-18
- Applications
- 2